|
![]() |
|
|
Fluorouracil
drug data and news
Fluorouracil drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Fluorouracil | ||
| Brand Names/Synonyms | 5 Fluorouracil; Adrucil; Arumel; Carac; Carzonal; Effluderm; Efudex; Efudix; Efurix; FT-207; FU; Fluoroblastin; Fluoroplex; Fluorouracil; Fluracil; Fluracilum; Fluri; Fluril; Fluro Uracil; Ftoruracil; Kecimeton; NSC 19893; NSC-19893; Phthoruracil; Phtoruracil; Queroplex; Timazin; U 8953; U-8953; URF; Ulup | ||
| Indication | For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, rectum, breast, stomach and pancrease. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand. | ||
| Mechanism Of Action | Fluorouracil inhibits thymidylate synthetase, leading to inhibition of DNA and RNA synthesis and cell death. | ||
| Fluorouracil News (When available) |
Merck cutting developing world AIDS drug price 20 pct 06 Mar 2006 CROI: early vs delayed Trizivir in TB/HIV coinfected - no ... Mar 2, 2006 AHF Applauds Idaho Medicaid for Placing Restrictions on Glaxo AIDS ... Feb 23, 2006 No aid for city AIDS patients in war over life-saving drugs Mar 3, 2006 Study eases concerns over mental side effects from potent AIDS ... Feb 2, 2006 Advances in First-Line and "Switch" Antiretroviral Strategies for ... Feb 2, 2006 CROI: Side effects, especially neuropathy and rash, common but ... Feb 8, 2006 CROI: Tenofovir and kidney toxicity - low rates seen, but some ... Feb 9, 2006 CROI News Feature: Experts divided over the future of treatment ... Feb 9, 2006 ImQuest Gains Dual-Mechanism HIV Compounds From Samjin Feb 28, 2006 CROI: abacavir may be safer than nevirapine in Africans Feb 8, 2006 Simplified treatment regimens show promise in HIV-infected ... Feb 6, 2006 Add new comment Feb 15, 2006 Anti-Retrovirals in Africa, not a distant dream Feb 9, 2006 Rapid scale-up of HIV treatment in Zambia Feb 7, 2006 US, Brazil Dispute Patent Protection Feb 24, 2006 CROI: Lipodystrophy stable in children on HIV treatment and does ... Feb 23, 2006 Medical Report Feb 3, 2006 Low Prevalence of Dyslipidemia Seen in Children on Non-Nucleoside ... Feb 7, 2006 Schering-Plough Presents Vicriviroc Clinical Study Results at 13th ... Feb 10, 2006 CROI: AZT, 3TC and FTC achieve good concentrations in the female ... Feb 17, 2006 Gilead Sciences Welcomes Guidance From Nice On Treatment Of ... Feb 22, 2006 Bill Clinton visits pharmaceutical plant in Goa Feb 18, 2006 70% still on first regimen after 3 years in Khayelitsha, but ... Feb 7, 2006 Adolescents Adherence to HIV Regimens Falls Short of Optimal ... Feb 7, 2006 CROI: etravirine (TMC125) and darunavir (TMC114) in treatment ... Feb 13, 2006 Schering-Plough Details Progress with HIV Drug Feb 10, 2006 Multi-component drug delivery system: An emerging trend Feb 8, 2006 Management of HIV/HBV Coinfection Feb 8, 2006 | ||
| Dosage Forms | Topical preparations, Solution for injection | ||
| Drug_Category | Immunosuppressive Agents; Antimetabolites; Antimetabolites; Antineoplastic Agents; ATC:L01BC02 | ||
| Absorption | 28-100% | ||
| Interactions |
-->Interactions for Fluorouracil: No information available. | ||
| Toxicity | LD50=230mg/kg (orally in mice) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 5-fluoro-1H-pyrimidine-2,4-dione | ||
| Chemical Formula | C4H3FN2O2 | ||
| Molecular Weight | 130.077 g/mol | ||
| Smiles String | C1=C(C(=O)NC(=O)N1)F | ||
| Melting Point | 280-282°C | ||
| Water Solubility | <0.1 g/100 mL at 19 C | ||
| State | white to practically white, crystalline powder | ||
| LogP/Hphobicity | -0.77 | ||
| Isoelectric Point | 8.02 | ||
| Biotransformation | Hepatic | ||
| Half Life | 10-20 minutes | ||
| Protein Binding [%] | 8-12% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Fluorouracil.html http://www.rxlist.com/cgi/generic3/carac.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00516 | ||
| CAS Registry Number | 51-21-8 | ||
| KEGG Compound ID | C07649 | ||
| PubChem ID | SID:323508 | ||
| PharmGKB ID | PA449672 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2182742 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |